These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 22208996)

  • 1. Generation and characterization of a functional Nanobody against the vascular endothelial growth factor receptor-2; angiogenesis cell receptor.
    Behdani M; Zeinali S; Khanahmad H; Karimipour M; Asadzadeh N; Azadmanesh K; Khabiri A; Schoonooghe S; Habibi Anbouhi M; Hassanzadeh-Ghassabeh G; Muyldermans S
    Mol Immunol; 2012 Feb; 50(1-2):35-41. PubMed ID: 22208996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of novel neutralizing single-chain antibodies against vascular endothelial growth factor receptor 2.
    Erdag B; Balcioglu BK; Bahadir AO; Serhatli M; Kacar O; Bahar A; Seker UO; Akgun E; Ozkan A; Kilic T; Tamerler C; Baysal K
    Biotechnol Appl Biochem; 2011; 58(6):412-22. PubMed ID: 22172104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibiting angiogenesis with human single-chain variable fragment antibody targeting VEGF.
    Hosseini H; Rajabibazl M; Ebrahimizadeh W; Dehbidi GR
    Microvasc Res; 2015 Jan; 97():13-8. PubMed ID: 25250517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiogenesis and radiation response modulation after vascular endothelial growth factor receptor-2 (VEGFR2) blockade.
    Li J; Huang S; Armstrong EA; Fowler JF; Harari PM
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1477-85. PubMed ID: 16029810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor.
    Sun J; Blaskovich MA; Jain RK; Delarue F; Paris D; Brem S; Wotoczek-Obadia M; Lin Q; Coppola D; Choi K; Mullan M; Hamilton AD; Sebti SM
    Cancer Res; 2004 May; 64(10):3586-92. PubMed ID: 15150116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation and characterization of a human nanobody against VEGFR-2.
    Ma L; Gu K; Zhang CH; Chen XT; Jiang Y; Melcher K; Zhang J; Wang M; Xu HE
    Acta Pharmacol Sin; 2016 Jun; 37(6):857-64. PubMed ID: 27108602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phage-derived fully human antibody scFv fragment directed against human vascular endothelial growth factor receptor 2 blocked its interaction with VEGF.
    Zhang J; Li H; Wang X; Qi H; Miao X; Zhang T; Chen G; Wang M
    Biotechnol Prog; 2012 Jul; 28(4):981-9. PubMed ID: 22581629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Necl-5/poliovirus receptor interacts with VEGFR2 and regulates VEGF-induced angiogenesis.
    Kinugasa M; Amano H; Satomi-Kobayashi S; Nakayama K; Miyata M; Kubo Y; Nagamatsu Y; Kurogane Y; Kureha F; Yamana S; Hirata K; Miyoshi J; Takai Y; Rikitake Y
    Circ Res; 2012 Mar; 110(5):716-26. PubMed ID: 22282193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical screening of anti-HER2 nanobodies for molecular imaging of breast cancer.
    Vaneycken I; Devoogdt N; Van Gassen N; Vincke C; Xavier C; Wernery U; Muyldermans S; Lahoutte T; Caveliers V
    FASEB J; 2011 Jul; 25(7):2433-46. PubMed ID: 21478264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human/mouse cross-reactive anti-VEGF receptor 2 recombinant antibodies selected from an immune b9 allotype rabbit antibody library.
    Popkov M; Jendreyko N; Gonzalez-Sapienza G; Mage RG; Rader C; Barbas CF
    J Immunol Methods; 2004 May; 288(1-2):149-64. PubMed ID: 15183093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-flt1 peptide, a vascular endothelial growth factor receptor 1-specific hexapeptide, inhibits tumor growth and metastasis.
    Bae DG; Kim TD; Li G; Yoon WH; Chae CB
    Clin Cancer Res; 2005 Apr; 11(7):2651-61. PubMed ID: 15814646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel role of ARF6 in vascular endothelial growth factor-induced signaling and angiogenesis.
    Ikeda S; Ushio-Fukai M; Zuo L; Tojo T; Dikalov S; Patrushev NA; Alexander RW
    Circ Res; 2005 Mar; 96(4):467-75. PubMed ID: 15692085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In-silico fragment-based identification of novel angiogenesis inhibitors.
    Dakshanamurthy S; Kim M; Brown ML; Byers SW
    Bioorg Med Chem Lett; 2007 Aug; 17(16):4551-6. PubMed ID: 17591441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A KDR-binding peptide (ST100,059) can block angiogenesis, melanoma tumor growth and metastasis in vitro and in vivo.
    Rastelli L; Valentino ML; Minderman MC; Landin J; Malyankar UM; Lescoe MK; Kitson R; Brunson K; Souan L; Forenza S; Goldfarb RH; Rabbani SA
    Int J Oncol; 2011 Aug; 39(2):401-8. PubMed ID: 21567086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intrabody-based strategies for inhibition of vascular endothelial growth factor receptor-2: effects on apoptosis, cell growth, and angiogenesis.
    Wheeler YY; Kute TE; Willingham MC; Chen SY; Sane DC
    FASEB J; 2003 Sep; 17(12):1733-5. PubMed ID: 12958192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anacardic acid (6-pentadecylsalicylic acid) inhibits tumor angiogenesis by targeting Src/FAK/Rho GTPases signaling pathway.
    Wu Y; He L; Zhang L; Chen J; Yi Z; Zhang J; Liu M; Pang X
    J Pharmacol Exp Ther; 2011 Nov; 339(2):403-11. PubMed ID: 21828260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PPARδ agonists suppress angiogenesis in a VEGFR2-dependent manner.
    Meissner M; Hrgovic I; Doll M; Kaufmann R
    Arch Dermatol Res; 2011 Jan; 303(1):41-7. PubMed ID: 21046127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel human anti-syndecan-1 antibody inhibits vascular maturation and tumour growth in melanoma.
    Orecchia P; Conte R; Balza E; Petretto A; Mauri P; Mingari MC; Carnemolla B
    Eur J Cancer; 2013 May; 49(8):2022-33. PubMed ID: 23352437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-VEGFR-2 scFvs for cell isolation. Single-chain antibodies recognizing the human vascular endothelial growth factor receptor-2 (VEGFR-2/flk-1) on the surface of primary endothelial cells and preselected CD34+ cells from cord blood.
    Böldicke T; Tesar M; Griesel C; Rohde M; Gröne HJ; Waltenberger J; Kollet O; Lapidot T; Yayon A; Weich H
    Stem Cells; 2001; 19(1):24-36. PubMed ID: 11209088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective blockade of vascular endothelial growth factor receptor 2 with an antibody against tumor-derived vascular endothelial growth factor controls the growth of human pancreatic adenocarcinoma xenografts.
    Holloway SE; Beck AW; Shivakumar L; Shih J; Fleming JB; Brekken RA
    Ann Surg Oncol; 2006 Aug; 13(8):1145-55. PubMed ID: 16791450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.